UNICREDIT BANK/CALL/AMGEN/500/0.1/14.01.26 | Market Closed - BOERSE MUENCHEN 20:40:33 17/05/2024 BST | ||
| 0.56 EUR | -5.08% |
|
| 1 month | +211.11% | ||
| 3 months | +80.65% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 0.56 | -5.08% |
| 16/05/24 | 0.59 | -4.84% |
| 15/05/24 | 0.62 | +19.23% |
| 14/05/24 | 0.52 | +1.96% |
| 13/05/24 | 0.51 | -8.93% |
Real-time BOERSE MUENCHEN
Last update May 17, 2024 at 08:40 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD28NE |
| ISIN | DE000HD28NE0 |
| Date issued | 29/01/2024 |
| Strike | 500 $ |
| Maturity | 14/01/2026 (605 Days) |
| Parity | 10 : 1 |
| Emission price | 0.67 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.73 € |
|---|---|
| Lowest since issue | 0.061 € |
| Spread | 0.02 € |
| Spread % | 3.57% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
312.5
USD
Average target price
314.1
USD
Spread / Average Target
+0.51%
- Stock Market
- Warrants
- Warrant
